KSQ Therapeutics
https://ksqtx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From KSQ Therapeutics
Mission Therapeutics Raises Funds For Parkinson’s Disease Protein Modulator
New funding for the UK biotech reflects growing interest in finding ways to remove dysfunctional proteins from the body.
Exelixis Adds Insilico Deal In Search Of Growth Beyond Cabometyx
After feeling the heat from activist investor Farallon Capital Management earlier this year, CEO Michael Morrissey has defended its spending on in-house R&D and in-licensing as it announced a new oncology deal.
Roche CEO Outlines M&A Criteria
Every year, Roche looks at “more than 1,000 companies and 99.9% of the time, we say no," says CEO Thomas Schinecker, though he stressed that the Swiss group is open to deals of any size.
Deal Watch: Sangamo Inks Significant Option Deal With Prevail After Losing Tie-Ups With Novartis, Biogen
Plus deals involving Novartis/DTx, Neurogene/Neoleukin, Travere/Mirum, Sanofi/Scribe, Korro Bio/Frequency, MaxCyte/viTToria and more.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- Genomics-Proteomics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice